Adagio Medical Holdings (ADGM) Research & Development (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 25.09% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (down 13.28% YoY), and the FY2025 full-year result was $10.6 million, up 129.59% from the prior year.
• Research & Development climbed to $2.7 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.4 million in Q3 2023 to a low of $1.2 million in Q3 2024.
• A 4-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development tumbled 72.45% in 2024 and jumped 127.94% in 2025, its largest moves.
• Tracing ADGM's Research & Development over 4 years: stood at $1.8 million in 2023, then tumbled by 31.4% to $1.2 million in 2024, then jumped by 83.65% to $2.2 million in 2025, then increased by 22.64% to $2.7 million in 2026.
• Business Quant data shows ADGM's Research & Development at $2.7 million in Q1 2026, $2.2 million in Q4 2025, and $2.8 million in Q3 2025.